

Assessing the Prevalence of Bacterial Vaginosis among Infertile Women in Thi- Qar Province, Iraq

ARTICLE INFO

Article Type Original Article

Authors

Sarmad Qassim Mohammad, *MSc*¹
Abdullah Khazal Mohsen, *MSc*²
Idriss Saleh Jalil, *MSc*¹
Osama Akram Mohsein, *MSc*^{3,4*}

¹ Technical Institute-Baqubah,
Middle Technical University,
Diyala, Iraq

² Al-Muqdad College of Education,
Diyala University, Diyala, Iraq

³ Department of Medical
Laboratory Techniques, Mazaya
University College, Thi-Qar, Iraq

⁴ Thi-Qar Health Directorate,
Al Habbobi Teaching Hospital,
Thi-Qar, Iraq Thi-Qar Health
Directorate, Al Habbobi Teaching
Hospital, Thi-Qar, Iraq

* Correspondence

¹Department of Medical Laboratory
Techniques, Mazaya University
College, Thi-Qar, Iraq

² Thi-Qar Health Directorate, Al Habbobi Teaching Hospital, Thi-Qar, Iraq.

E-mail: osamaakram889@gmail.com

How to cite this article

Mohammad S.Q., Mohsen A., Jalil I.S., Mohsein O.A. Assessing the Prevalence of Bacterial Vaginosis among Infertile Women in Thi- Qar Province, Iraq. *Infection Epidemiology and Microbiology*. 2024;10(4): 287-296.

Article History

Received: March 04, 2024

Accepted: November 26, 2024

Published: December 20, 2024

ABSTRACT

Background: This study aimed to elucidate the predominant bacterial species implicated in the etiology of vaginosis and to determine the most effective antimicrobial agents for their therapeutic management in Iraq.

Materials & Methods: Swab samples were collected through speculum-assisted vaginal examination. The process involved inserting a swab into the vaginal canal and rotating it for at least eight seconds before pulling it out. Standard procedures including microscopy, culture, and antibiotic sensitivity testing were applied to analyze vaginal swab samples.

Findings: *Staphylococcus aureus* was identified as the most common Gram-positive bacterium involved in bacterial vaginosis (44.3 %). *Serratia* species, were not detected at all (0.0 %). Among the Gram-negative bacteria, *Klebsiella* was the most prevalent bacterium (at 18.8%), followed by *Escherichia coli* at (18.1 %). *Candida* was detected in 9.4% of cases. In antibiotic susceptibility testing, *S. aureus* exhibited maximum resistance to imipenem (100%) and high susceptibility to penicillin, vancomycin, and clindamycin. Gentamicin was the most effective antibiotic against *E. coli* and *Klebsiella spp*, while vancomycin was highly effective against *Candida*. These results, indicate that the treatment should be directed towards the antibiotics to which the bacteria show the highest sensitivity to achieve optimal therapeutic outcomes.

Conclusion: *S. aureus* was identified as the most common vaginal pathogen in Thi-Qar province, followed by *Klebsiella spp.*, and *E. coli*, respectively. These findings provide valuable insights into the prevalence of different bacterial species and the most effective medications. The results will be invaluable for future prospective investigations.

Keywords: Vaginosis, Gram-negative bacteria, Gram-positive bacteria, Antimicrobial resistance, Sexually transmitted diseases.

CITATION LINKS

[1] Ravel J, Vaginal microbiome of... [2] Zhou X, et al. Differences in... [3] Witkin S.S. Bacterial flora of... [4] Brunham R.C. Pelvic inflammatory... [5] Allsworth J.E., Peipert J.F. Prevalence of... [6] Fredricks D.N. Molecular identification... [7] Ghiasi M. Assessing the... [8] Muzny C.A. et al. Identification... [9] Atashili J. Bacterial vaginosis... [10] Leitich H. Bacterial vaginosis... [11] Bautista, T. Bacterial vaginosis:... [12] Bautista C.T. Association of... [13] Weström L. Pelvic inflammatory... [14] Haggerty C.L. PID Evaluation and... [15] Swidsinski A. et al. Adherent... [16] Leitich H. Asymptomatic... [17] Wilson JD. Rates of bacterial... [18] Menard JP. Antibacterial... [19] Bitew A. Prevalence of... [20] Nzomo J. Bacterial vaginosis... [21] Javed A. Bacterial vaginosis... [22] Aduloju OP. Prevalence of... [23] Kamga YM. Prevalence of... [24] Van Oostrum, Noortje, et al. «Risks associated... [25] Ischenko, I. «Influence Of... [26] Donders GG. Definition of... [27] Krauss-Silva L. Basic vaginal... [28] Nasim MJ, et al. Pronounced activity... [29] Venter H. RND-type drug... [30] Mulu W. Common causes... [31] Howe R. Bacterial profile... [32] Akram M, Etiology and... [33] Linhares I. Frequency and... [34] Jang, Soojin. «AcrAB- TolC... [35] Odonkor ST. Bacteria resistance... [36] Shrivastava SR,. World Health Organization... [37] Reid G, Bruce AW. Urogenital... [38] Aslim B, Kilic E. Some probiotic... [39] Charlier C. Interactions between... [40] Mibbard LT, Snyder WJ. Subgluteal and... [41] Kent HL. Epidemiology of... [42] Hafiz S, et al. Methicillin...

Introduction

The vaginal microbiota of healthy women of reproductive age is typically composed of aerobic, facultative anaerobic, and obligate anaerobic bacteria. In most women, *Lactobacilli* form a large portion of the vaginal flora [1-2]. Vaginal microbiota maintains a healthy balance by producing lactic acid, and antibiotic compounds, and stimulating the immune system at a basal level to inhibit the growth of harmful bacteria [3]. An imbalance in the type and number of *Lactobacilli* could lead to increased susceptibility to sexually transmitted infections (STIs) and upper genital tract infections by allowing the growth of bacterial pathogens and anaerobic bacteria [4]. Bacterial vaginosis is a common bacterial infection that affects the lower part of the vagina, affecting 29% of women of reproductive age in the United States [5]. A study in Qom revealed that the number of fully identified Gram-positive bacteria involved in BV was much higher than that of fully identified Gram-negative bacteria, and it was found that 70.34% of women who were unable to conceive had bacterial vaginosis. The most prevalent vaginal pathogens were *Staphylococcus aureus* (57.33%) and *Escherichia coli* (*E. coli*) (25.33%), penicillin and gentamicin were the most effective antibiotics against *S. aureus* [7]. Common bacteria associated with BV include *Gardnerella vaginalis*, *Megasphaera* spp., *Atopobium vaginae*, *Dialister* spp., *Mobiluncus* spp., *Sneathia amnii*, *S. sanguinegens*, *Porphyromonas* spp., and *Prevotella* spp [6-8]. While BV often presents no symptoms, women with BV are more prone to vaginal odor, irritation, and discharge compared to those without BV [9]. Serious health risks linked to BV include increased risk of infertility, adverse pregnancy outcomes, STIs such as *Chlamydia*, *Gonorrhea*, human papillomavirus (HPV), and human immunodeficiency virus (HIV)

infections, along with pelvic inflammatory diseases (PID) like endometritis [10]. It is estimated that 20–30 % of women with vaginal discharge have BV, although the prevalence could reach 50–60 % in some populations with high-risk sexual behaviors [11]. PID and endometritis are upper vaginal infections that could present with various clinical symptoms and signs. Acute (PID) occurs when stringent or facultative anaerobic bacteria move from the vagina to the endometrium and adnexa within a 30-day timeframe [12]. Chronic endometritis is a persistent infection lasting 30 days or more. Bacteria associated with BV and/or STIs are responsible for more than 85% of PID cases. Less than half of PID cases are attributed to *Neisseria gonorrhoeae* or *Chlamydia trachomatis*. The presence of anaerobic bacteria, linked to BV and other diseases, such as *Mycoplasma genitalium*, plays a significant role in the development of endometritis and PID. Both endometritis and PID are linked to numerous adverse health outcomes, including chronic discomfort, ectopic pregnancy, tubo-ovarian abscess, and infertility [13-14]. The vagina typically harbors indigenous *Lactobacilli* that make up the normal vaginal microbiota. BV is associated with a decrease in *Lactobacilli*, which are usually the dominant bacteria, and an increase in other anaerobes forming a polymicrobial biofilm on the vaginal epithelium [15]. BV is the most common cause of vaginal discharge worldwide but, is asymptomatic in at least 50% of cases. A large body of research suggests that the harmful impacts of BV extend beyond the lower genital tract. BV is closely linked to reproductive issues, including late fetal loss and preterm birth [16]. Multiple studies have demonstrated a high occurrence of BV in individuals with infertility. However, the specific challenges that infertile patients with BV face in terms of pregnancy outcomes

have not been definitively determined [17]. Studies also face several challenges, including antibiotic resistance in bacteria due to genetic mutations and changes that occur in bacterial strains, which complicates the antibiotic sensitivity process and impacts the effectiveness of the antibiotics used. In addition, issues related to the study design, sample, and statistical methods used present further challenges.

Objectives: The goal of this study was to identify the most common causes of BV responsible for infertility in women and to determine the most effective antibiotics to treat these specific pathogens in clinical settings. In this study, vaginal samples of women with vaginitis were collected and analyzed by cultured and microscopy specific groups of bacteria were identified, and their frequency and drug sensitivity were determined.

Materials and Methods

Study design: In this study, a total of 150 high vaginal swab (HVS) samples were collected from women in the women's wards of Al-Haboubi Teaching Hospital in Al-Nasiriyah city (center of Thi-Qar province in southern Iraq) from January to October 2024. The patients' age ranged from 25 to 35 years. Standard microbiological procedures were employed to examine the collected HVS samples with various bacterial colors.

Sample collection: After obtaining signed written informed consent from the patients, all samples were taken during vaginal examination using a speculum that was moistened with normal saline before use, avoiding the use of antiseptic cream that could adversely affect bacteria and yeasts. Once the speculum was placed into the vaginal mucosa the swab was inserted into the vaginal opening, rotated for 8 seconds, and then removed. The vaginal swabs were then subjected to traditional microbiological

analysis, including microscopy, culture, and antibiotic susceptibility testing.

Isolation and identification: Using conventional microbiological techniques, the presence of yeast, *S. aureus*, *Enterococcus*, and microaerobic and aerobic bacteria was detected in the specimens collected. BV was diagnosed using Gram-stained smear technique. Mueller-Hinton agar, Eosin-methylene blue (EMB) agar, and blood agar plates were streaked to cultivate the samples. The plates were then incubated at 37-°C in an oxygen-controlled chamber for 2 days. While some plates showed growth features of the isolates, many plates showed no growth. The cultures were purified through sub-culturing and stored in a refrigerator for further research. Bacteria collected from vaginitis were identified under aerobic conditions using Gram -staining and conventional biochemical tests such as catalase, oxidase, Mmannitol salt agar (MSA), and hemolysis tests. Hemolytic effects on human blood agar media helped identify *Streptococcus* and *Enterococcus* species. Various methods were used to identify Gram-negative bacteria, including Gram staining that appears red, culture on different media, and biochemical tests like oxidase, catalase, carbohydrate fermentation, and analytical profile index (API) tests.

Antimicrobial susceptibility testing: Each colony was cultured overnight in nutrient broth to assess the isolates' sensitivity to antibiotics. After immersing the sterile swab in the bacterial solution, it was streaked across the Mueller-Hinton agar medium. to ensure even bacterial distribution. Antibiotic discs containing ampicillin, ceftriaxone, imipenem, cephalazolin, gentamicin, nitrofurantoin, penicillin, streptomycin, vancomycin, clindamycin, erythromycin, and oxacillin were placed on the agar plates with precise spacing. In addition, the efficacy of various antifungal discs placed on Mueller Hinton agar

plates was evaluated against *Candida*. In this study, all antibiotic discs used were from Liofilchem Co. (Liofilchem, Inc., Italy). Sensitivity analyses were performed according to CLSI standards issued in 2023 using standard strains of *E. coli* (ATCC 25922) and *S. aureus* (ATCC 29213) as controls to validate the test results.

Ethical approval: The Declaration of Helsinki ethical guidelines for medical research involving human subjects were strictly followed in the conduct of the present investigation (2013). Before collecting the samples, all patients included in this study were properly informed about the research objectives and gave their verbal permission. This study was approved by the Publication Ethics Committee at Thi-Qar Health Directorate, Al Habbobi Teaching Hospital, (No: 645 in August 29, 2023).

Statistical analysis: SPSS software version 26 was used for data analysis (SPSS Software, Inc., Chicago, Ill, USA). Chi-square test was used to evaluate variations in prevalence by gender, age group, and geographic location.

Study limitations: The study faces several constraints, including its focus on a limited subset of participants, which may not fully represent the wider population. Self-reported data from participants may introduce bias when assessing symptoms. Factors such as personal hygiene practices, hormonal influences, and prior antibiotic use could alter the study results. There are also challenges associated with long-term monitoring of treatment effectiveness and its impact on vaginal flora.

Findings

Frequency and percentage of Gram-positive bacterial vaginosis in the study group: In this study, *S. aureus* was identified as the most common Gram-positive bacterium involved in bacterial vaginosis and found in 66 cases (44.3%),

and *Enterococcus* was present in three cases (2.0%). The results also revealed that the frequency of *Group B Streptococcus* was four cases (2.7%) (Table 1).

Frequency and percent of Gram-negative bacterial vaginosis and *Candida* among the study: *E. coli* was identified in 27 (18.1%) samples, *Klebsiella* was identified in 28 (18.8%) samples, *Proteus vulgaris* (*P. vulgaris*) was identified in three (2.0%) cases, *Pseudomonas aeruginosa* (*P. aeruginosa*) was identified in four (2.7%), and *Serratia* was not identified at all (0.0%) (Table 2).

Antibiotic susceptibility/resistance of Gram-positive bacteria involved in BV among the study group: antibiotic susceptibility testing results of Gram-positive bacterial isolates were as, follows (Table 3): *S. aureus* showed complete sensitivity (S) to penicillin, gentamicin, and vancomycin. However, it was entirely resistant (R) to imipenem and demonstrated varying degrees of intermediate resistance (I) to cep-

Table 1) Frequency and percentage of Gram positive bacteria among the study group

Spp.	Frequency	Percentage
<i>Staphylococcus aureus</i>	66	44.3%
<i>Enterococcus</i>	3	2.0%
<i>Group B Streptococcus</i>	4	2.7%

Table 2) Frequency and percentage of Gram-negative bacteria and *Candida* among the study group.

Spp.	Frequency	Percentage
<i>E.coli</i>	27	18.1%
<i>Klebsiella</i>	28	18.8%
<i>Proteus Vulgaris</i>	3	2.0%
<i>Pseudomonas aeruginosa</i>	4	2.7%
<i>Serratia</i>	0	0.0%

alosporins. *Enterococcus* bacteria exhibited complete resistance to ampicillin, penicillin, and oxacillin, with all samples proving impervious. However, partial resistance was shown to ceftriaxone, erythromycin, and vancomycin. *Group B Streptococcus* bacteria

displayed complete sensitivity to cefazolin, but revealed resistance to penicillin, erythromycin, ampicillin, and nitrofurantoin. Notably, gentamicin was primarily effective against *S. aureus*, whereas these isolates showed varying levels of resistance to

Table 3) Antibiotic susceptibility/resistance of Gram-positive bacteria

Variable		<i>S. aureus</i>	<i>Enterococcus</i>	<i>Group B Streptococcus</i>
Ampicillin	S (No.)	0	0	0
	I (No.)	66	0	0
	R (No.)	0	3	4
Ceftriaxone	S (No.)	66	0	0
	I (No.)	0	2	0
	R (No.)	0	1	4
Imipenem	S (No.)	0	0	0
	I (No.)	0	2	0
	R (No.)	66	1	4
Cefazolin	S (No.)	0	0	4
	I (No.)	26	0	0
	R (No.)	40	3	0
Gentamicin	S (No.)	61	0	0
	I (No.)	0	2	4
	R (No.)	5	1	0
Nitrofurantoin	S (No.)	0	0	0
	I (No.)	29	2	0
	R (No.)	37	1	4
Vancomycin	S (No.)	66	0	0
	I (No.)	0	0	4
	R (No.)	0	3	0
Oxacillin	S (No.)	44	0	0
	I (No.)	22	3	4
	R (No.)	0	0	0
Penicillin	S (No.)	66	0	0
	I (No.)	0	0	0
	R (No.)	0	3	4
Erythromycin	S (No.)	10	0	0
	I (No.)	56	0	0
	R (No.)	0	3	4
Clindamycin	S (No.)	66	0	0
	I (No.)	0	3	4
	R (No.)	0	0	0

S: Sensitivity; I: Intermediate; R: resistance

ampicillin, imipenem, and cephalosporins. It is crucial to note that these data emphasize the need to determine suitable treatments based on lab susceptibility testing. This approach avoids the evolution of resistant bacterial strains and ensures the best therapeutic outcomes for patients.

Antibiotic susceptibility/resistance of

Gram-negative bacteria and *Candida* involved in BV among the study group:

The current study aimed to determine bacterial sensitivity to a selected group of antibiotics,. The following results were obtained: *E. coli* bacteria showed no complete sensitivity to ampicillin, although one fifth of the samples showed moderate sensitivity.

Table 4) Antibiotic susceptibility/resistance of Gram negative bacteria and *Candida*

Variable		<i>E.coli</i>	<i>Klebsiella</i>	<i>P. vulgaris</i>	<i>P. aeruginosa</i>	<i>Candida</i>
Ampicillin	S (No.)	0	0	0	4	0
	I (No.)	27	0	0	0	2
	R (No.)	0	28	3	0	12
Ceftriaxone	S (No.)	27	0	0	0	2
	I (No.)	0	0	0	0	0
	R (No.)	0	28	3	4	12
Imipenem	S (No.)	27	0	0	0	0
	I (No.)	0	1	0	0	12
	R (No.)	0	27	3	4	2
Cefazolin	S (No.)	20	0	0	0	0
	I (No.)	7	28	0	0	12
	R (No.)	0	0	3	4	2
Gentamicin	S (No.)	27	1	0	0	14
	I (No.)	0	27	3	4	0
	R (No.)	0	0	0	0	0
Nitrofurantoin	S (No.)	0	0	0	0	0
	I (No.)	0	0	3	4	1
	R (No.)	27	28	0	0	13
Vancomycin	S (No.)	0	1	3	4	14
	I (No.)	22	0	0	0	0
	R (No.)	5	27	0	0	0
Oxacillin	S (No.)	0	0	0	4	2
	I (No.)	21	28	0	0	12
	R (No.)	6	0	3	0	0
Penicillin	S (No.)	0	1	3	0	14
	I (No.)	19	27	0	0	0
	R (No.)	8	0	0	4	0
Erythromycin	S (No.)	0	0	0	0	0
	I (No.)	13	27	3	4	2
	R (No.)	14	1	0	0	12
Clindamycin	S (No.)	0	0	3	0	2
	I (No.)	17	28	0	4	12
	R (No.)	10	0	0	0	0

Both *Klebsiella* and *Proteus vulgaris* did not exhibit any susceptibility to this antibiotic, while all *P. aeruginosa* isolates were sensitive. The majority of *Candida* isolates showed presented resistance to ampicillin and ceftriaxone. *E.coli* bacteria demonstrated complete sensitivity to ceftriaxone, while *Klebsiella* and *Proteus* bacteria showed complete resistance, and some sensitivity was found in *Candida* samples. Imipenem was effective against *E. coli*, although most *Klebsiella* samples showed resistance, with moderate susceptibility observed in one sample. Resistance to imipenem was also detected in *P. vulgaris*, *P. aeruginosa*, and *Candida* isolates. Regarding cefazolin, data analyses results showed varying degrees of sensitivity to *E. coli* isolates, with intermediate resistance in *Klebsiella* and complete resistance in *P. vulgaris*, and *Pseudomonas aeruginosa*.

Resistance to nitrofurantoin was manifested in *E. coli* and *Klebsiella*, but no sensitivity was observed in *P. vulgaris*, *P. aeruginosa*, or *Candida* isolates. *Klebsiella*, *P. vulgaris*, and *P. aeruginosa* showed partial to complete sensitivity to vancomycin, while *Candida* demonstrated complete sensitivity. *P. aeruginosa* was sensitive to oxacillin, while the remaining samples were moderately sensitive or resistant. Similarly to vancomycin, both *Klebsiella* and *P. vulgaris* demonstrated partial to complete sensitivity to penicillin. None of the bacteria showed high sensitivity to erythromycin and clindamycin, and they were generally resistant.

These results suggest significant variations in bacterial susceptibility and resistance to antibiotics, which should be considered when prescribing them for the treatments of bacterial and fungal infections. Thus, treatment should be guided by antibiotic susceptibility testing results to achieve optimal therapeutic outcomes.

Discussion

BV is a common infection of the lower vaginal tract in women of reproductive age. It often leads to foul-smelling vaginal discharge, lowers pregnancy success rates, and increases the risk of sexually transmitted illnesses [18]. This study examined the prevalence of BV among women struggling to conceive, underscoring the importance of detecting and treating infectious vaginitis. To identify the most effective treatment for BV, causative bacteria were isolated through sub-culturing and tested for resistance and susceptibility to various medications. The study found a prevalence rate of 81.20% for BV among infertile women. *S. aureus* was the most dominant vaginal pathogen, accounting for 44.3% of cases, followed by *Klebsiella spp.* (18.8%), *E. coli* (18.1%), and *Candida* at (9.4%). *S. aureus* was highly susceptible to ceftriaxone, vancomycin, penicillin, and clindamycin, indicating that this bacterium has not developed resistance to penicillin in Thi-Qar. *E. coli* was most susceptible to imipenem, cefphazolin, and gentamicin, while *Klebsiella* displayed high resistance to most drugs. These results align with the results of other studies conducted in Addis Ababa (41.5%) [19], Kenya (43.1%) [20], Nigeria (37%), and Cameroon [20]. (38%), highlighting BV as a significant concern for Ethiopian women throughout their reproductive years [21-24]. The current study findings are also comparable to the findings of previous research in India regarding the prevalence of *S. aureus* (41.07%). In Addis Ababa, there were 43 and 28 BV cases caused by *E. coli* (41%) and *K. pneumoniae* (30.5%), respectively [23]. Studies in the United States and Belgium have reported unspecified and 42. BV cases reported, respectively [24]. Of the 163 samples of *G. vaginalis*, 37 (22.7% of the total) samples were identified using the Nugent scoring technique in the Cameroon. These findings are lower than those reported

in Cameroon (38%) and Gambia (44.4%) but were consistent with the results of an Italian study (26.62%) [25-27]. Therefore, BV remains a significant global health issue for women, particularly pregnant women or those trying to conceive. While the number of pharmaceutical companies researching and producing new antimicrobial drugs has decreased, the prevalence of microorganisms resistant to multiple drugs has increased dramatically over the past 20 years. Concerns about the spread of antibiotic-resistant bacteria are a top priority for international health agencies, especially in countries with insufficient funding to combat this issue [28-29]. In the current research, the drug susceptibility pattern of aerobic bacteria was identified using a standard culture medium. *S. aureus* demonstrated the highest sensitivity to vancomycin, penicillin, and clindamycin. Fortunately, in Thi-Qar, this bacterium has not yet developed resistance to penicillin. *E. coli* showed the highest susceptibility to imipenem, cefazolin, and gentamicin. *Klebsiella spp.* exhibited high resistance to the majority of drugs. These findings align with the results of other studies conducted in Bahir Dar [30], Gondar [31], Addis Ababa [18], India [32], and Portugal [33]. Gram-negative bacteria possess a more intricate biological structure than Gram-positive bacteria, which creates a barrier affecting permeability and supports the operation of drug efflux pumps. Gram-negative bacteria display more antibiotic resistance than Gram-positive bacteria [34]. Antibiotic-resistant bacteria employ various methods to evade antibiotic effects, such as removing the medicine from the cell, changing the target site, and altering the folic acid production pathway [35]. The future strategy of the World Health Organization (WHO) will prioritize the research and development of novel antibiotics targeting Gram-negative bacteria resistant to multiple

drugs and broad-spectrum antibiotics [36]. Local health practitioners should apply the latest antibiotics recommended by the WHO. Instead of prescribing broad-spectrum antibiotics, medical professionals should administer narrow-spectrum medications based on the results of antibiotic susceptibility tests. *Lactobacillus* comprises a significant portion of the bacteria in a healthy, stable vaginal environment [37, 38]. *S. aureus*, an opportunistic pathogen, exists in the vaginal microbiota of multiple hosts. Many complex factors allow *Lactobacillus* to inhibit the growth of *S. aureus*. In cases of BV, *S. aureus* infection disrupts the natural bacterial flora [39]. *C. albicans* is implicated in 80–92% of yeast infections. However, in this investigation, the prevalence of *Candida* infection was lower than anticipated (9.4%). While *Candida* infection accounts for roughly one-third of all vaginitis cases, our findings are inconsistent with this frequency [40-41]. Bacterial vaginosis (BV) is typically treated with specific antibiotics. To gauge the susceptibility or resistance of the isolated bacteria and yeast, several antibiotic discs were used in this study. *S. aureus* was found to be highly susceptible to penicillin. However, a study in Pakistan reported that *S. aureus* has exhibited developed resistance to penicillin, with just 26.3% of the strains being susceptible to ampicillin. This resistance to penicillin is primarily due to the presence of β -lactamases. Therefore, combining penicillin with a β -lactamase inhibitor produces better results [42]. The study faces several constraints, including its focus on a limited subset of participants, which may not fully represent the wider population. Self-reported data from participants may introduce bias when assessing symptoms. Factors such as personal hygiene practices, hormonal influences, and prior antibiotic use could alter the study results. There are also challenges associated with long-term

monitoring of treatment effectiveness and its impact on vaginal flora.

Conclusion

The disparity between the frequency of Gram-positive and Gram-negative bacteria involved in BV was substantial. It was found that 81.20% of women who were unable to conceive suffered from BV. *S. aureus* was the most prevalent vaginal pathogen (44.3%), followed by *Klebsiella spp.* (18.8%), *E. coli* (18.1%), and *Candida* (9.4%). *S. aureus* was primarily susceptible to ceftriaxone, vancomycin, penicillin, and clindamycin. *E. coli* was highly susceptible to ceftriaxone, imipenem, cefazolin, and gentamicin. However, *Klebsiella spp.* showed resistance to many drugs. It is crucial for physicians to stay vigilant and utilize available screening methodologies to rapidly detect and treat BV patients.

Acknowledgements

The authors would like to thank the staff of the Environmental Health Unit at Thi-Qar Health Directorate Teaching Hospital. We are extremely grateful to the staff of the department laboratory in Al-Habbobi Teaching Hospital for protecting and improving the environment.

Ethical permissions: The Declaration of Helsinki ethical guidelines for medical research involving human subjects were strictly followed in the conduct of the present investigation (2013). Before collecting the samples, all patients included in this study were properly informed about the research objectives and gave their verbal permission. This study was approved by the Publication Ethics Committee at Thi-Qar Health Directorate, Al Habbobi Teaching Hospital, (No: 645 in 29/8/2023).

Authors' contributions: SQM: contributed to study design, literature review, and analysis; AKM: contributed to experimental

analysis, samples collection, and obtaining ethical approval; ISJ: contributed to data analysis, experimental analysis, and data collection; OAM: contributed to study design, sample collection, and data analysis. All authors were contributed to the writing, reviewing, and final proofing of the article.

Conflicts of interests: The authors declare that they have no competing interests.

Fundings: Self-funded by authors.

Consent to participate: Ethical approval was obtained from all participants in the research and they signed the ethical agreement forms according to the instructions of the Ethical Approvals Department at Al-Habbobi Teaching Hospital. All patient information was recorded.

References

1. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, et al. Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci.* 2011;108(Suppl 14):4680-7.
2. Zhou X, Brown C.J., Abdo Z, Davis CC, Hansmann MA, Joyce P, et al. Differences in the composition of vaginal microbial communities found in healthy Caucasian and black women. *ISME J.* 2007; 1(2): 121-33.
3. Witkin S.S., Linhares I.M., Giraldo P. Bacterial flora of the female genital tract: Function and immune regulation. *Best Pract Res Clin Obstet Gynaecol.* 2007; 21(3): 347-54.
4. Brunham R.C., Gottlieb S.L., Paavonen J. Pelvic inflammatory disease. *N Engl J Med.* 2015; 372(21): 2039-48.
5. Allsworth J.E., Peipert J.F. Prevalence of bacterial vaginosis: 2001–2004 national health and nutrition examination survey data. *Obstet Gynecol.* 2007; 109(1): 114-120.
6. Fredricks D.N., Fiedler T.L., Marrazzo J.M. Molecular identification of bacteria associated with bacterial vaginosis. *N Engl J Med.* 2005; 353(18): 1899-911.
7. Ghiasi M, Fazaeli H, Kalhor N, Sheykh-Hasan M, Tabatabaei-Qomi R. Assessing the prevalence of bacterial vaginosis among infertile women of Qom city. *Iran J Microbiol.* 2014
8. Muzny C.A., Blanchard E., Taylor C.M., Aaron KJ, Talluri R, Griswold ME, et al. Identification of key bacteria involved in the induction of incident bacterial vaginosis: A prospective study. *J Infect Dis.* 2018; 218(6): 966-78.

9. Atashili J., Poole C., Ndumbe P.M., Adimora A.A., Smith J.S. Bacterial vaginosis and HIV acquisition: A meta-analysis of published studies. *AIDS*. 2008; 22(12): 1493-501.
10. Leitich H., Bodner-Adler B., Brunbauer M., Kaidler A., Egarter C., Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: A meta-analysis. *Am J Obstet Gynecol*. 2003; 189(1): 139-147.
11. Bautista, T., Wurapa EK, Saterren WB, Morris S, Hollingsworth B, Sanchez J. "Bacterial vaginosis: A synthesis of the literature on etiology, prevalence, risk factors, and relationship with chlamydia and gonorrhea infections." *Mili Med Res* (2016;3): 1-10.
12. Bautista C.T., Wurapa E.K., Saterren W.B., Morris S.M., Hollingsworth B.P., Sanchez J.L. Association of bacterial vaginosis with chlamydia and gonorrhea among women in the U.S. army. *Am J Prev Med*. 2017; 52(5): 632-9
13. Weström L., Joeseof R., Reynolds G., Hagdu A., Thompson S.E. Pelvic inflammatory disease and fertility: A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. *Sex Transm Dis*. 1992; 19(4): 185-92.
14. Haggerty C.L., Hillier S.L., Bass D.C., Ness R.B., PID Evaluation and Clinical Health Study Investigators. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. *Clin Infect Dis*. 2004; 39(7): 990-5
15. Swidsinski A, Mendling W, Loening-Baucke V, Ladhoff A, Swidsinski S, Hale LP, et al. Adherent biofilms in bacterial vaginosis. *Obstet Gynecol*. 2005;106(5):1013-23.
16. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome. *Best Pract Res Clin Obstet Gynaecol*. 2007;21(3):375-90.
17. Wilson JD, Ralph SG, Rutherford AJ. Rates of bacterial vaginosis in women undergoing in vitro fertilization for different types of infertility. *BJOG*. 2002;109(6):714-7.
18. Menard JP. Antibacterial treatment of bacterial vaginosis: Current and emerging therapies. *Int J Womens Health*. 2011;3:295-305.
19. Bitew A, Abebaw Y, Bekele D, Mihret A. Prevalence of bacterial vaginosis and associated risk factors among women complaining of genital tract infection. *Int J Microbiol*. 2017;2017(1):1-8.
20. Nzomo J, Waiyaki P, Waihenya R. Bacterial vaginosis and correlates in women of reproductive age in Thika, Kenya. *Adv Microbiol*. 2013; 3(3):249-54.
21. Javed A, Parvaiz F, Manzoor S. Bacterial vaginosis: An insight into the prevalence, alternative treatments regimen, and its associated resistance patterns. *Microb Pathog*. 2019;127:21-30.
22. Aduloju OP, Akintayo AA, Aduloju T. Prevalence of bacterial vaginosis in pregnancy in a tertiary health institution, south western Nigeria. *Pan Afr Med J*. 2019;33(1):1-9.
23. Kamba YM, Ngunde JP, Akoachere J-F. Prevalence of bacterial vaginosis and associated risk factors in pregnant women receiving antenatal care at the Kumba health district (KHD), Cameroon. *BMC Pregnancy Childbirth*. 2019;19:1-8.
24. Van Oostrum, Noortje, et al. "Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis." *Human reproduction* 28.7 (2013): 1809-1815.
25. Ischenko, I. "Influence Of Hormonal Level In Women Of Fertile Age With Bacterial Vaginosis." *Science and innovation* 2.D11 (2023): 439-441.
26. Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: Aerobic vaginitis. *BJOG*. 2002;109(1):34-43.
27. Krauss-Silva L, Almada-Horta A, Alves MB, Camacho KG, Moreira MEL, Braga A. Basic vaginal pH, bacterial vaginosis and aerobic vaginitis: Prevalence in early pregnancy and risk of spontaneous preterm delivery, a prospective study in a low socioeconomic and multiethnic South American population. *BMC Pregnancy Childbirth*. 2014;14(1):1-10.
28. Nasim MJ, Witek K, Kincses A, Abdin AY, Żesławska E, Marć MA, et al. Pronounced activity of aromatic selenocyanates against multidrug resistant ESKAPE bacteria. *New J Chem*. 2019;43(15):6021-31.
29. Venter H, Mowla R, Ohene-Agyei T, Ma S. RND-type drug efflux pumps from Gram-negative bacteria: Molecular mechanism and inhibition. *Front Microbiol*. 2015;6:377.
30. Mulu W, Yimer M, Zenebe Y, Abera B. Common causes of vaginal infections and antibiotic susceptibility of aerobic bacterial isolates in women of reproductive age attending at Felegehiwot referral hospital, Ethiopia: A cross sectional study. *BMC Women's Health*. 2015;15(1):1-942.
31. Howe R, Bitew A, Dagnew M, Tegenie B, Yeshitila B, Abate E. Bacterial profile, antibacterial susceptibility pattern, and associated factors among women attending antenatal and postnatal health service at the University of Gondar Teaching Hospital, northwest Ethiopia. *Ethiop Med J*. 2019;57(3):9-22.
32. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. *Ann Clin Microbiol Antimicrob*. 2007;6(1):1-74.
33. Linhares I, Raposo T, Rodrigues A, Almeida A.

- Frequency and antimicrobial resistance patterns of bacteria implicated in community urinary tract infections: A ten-year surveillance study (2000–2009). *BMC Infect Dis.* 2013;13:1-14.
34. Jang, Soojin. "AcrAB– TolC, a major efflux pump in Gram negative bacteria: toward understanding its operation mechanism." *BMB reports* 56.6 (2023): 326.
 35. Odonkor ST, Addo KK. Bacteria resistance to antibiotics: Recent trends and challenges. *Int J Biol Med Res.* 2011;2(4):1204–10.
 36. Shrivastava SR, Shrivastava PS, Ramasamy J. World Health Organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. *J Med Soc.* 2018;32(1):76-7.
 37. Reid G, Bruce AW. Urogenital infections in women: Can probiotics help? *Postgrad Med J.* 2003;79(934):428–432.
 38. Aslim B, Kilic E. Some probiotic properties of vaginal lactobacilli isolated from healthy women. *Jpn J Infect Dis.* 2006;59(4):249–53.
 39. Charlier C, Cretenet M, Even S, Le Loir Y. Interactions between *Staphylococcus aureus* and lactic acid bacteria: An old story with new perspectives. *Int J Food Microbiol.* 2009;131(1):30–9.
 40. Mibbard LT, Snyder WJ. Subgluteal and retrosoas infections in obstetrical practice. *J Obstet Gynecol.* 1972;39(1):137–9.
 41. Kent HL. Epidemiology of vaginitis. *Am J Obstet Gynecol.* 1991;165(4):1168-76.
 42. Hafiz S, Hafiz AN, Ali L, Chughtai AS, Memon B, Ahmad A, et al. Methicillin resistant *Staphylococcus aureus*; A multicentre study. *J Pak Med Assoc.* 2002;52(7):312–5.